Aptose Biosciences Inc.

As of March 31, 2025, Aptose Biosciences Inc. has 2.55M shares outstanding.

These figures are as of March 31, 2025.

As of March 31, 2025, Aptose Biosciences Inc. maintains a current ratio of 1.10, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -121.51, indicating conservative leverage, while an interest coverage ratio of -256.71 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended March 31, 2025. Return on assets (ROA) is negative at -210.56, reflecting losses generated across the asset base.

As of the close on February 10, 2026, Aptose Biosciences Inc.'s stock has declined approximately 68.91% over the past 52 weeks. The 50-day moving average sits at 2.96, while the 200-day moving average is 8.39.

These figures cover the twelve months ended March 31, 2025. Free cash flow yield is negative at -778.67: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -645.67, meaning Aptose Biosciences Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Aptose Biosciences Inc.'s most recent stock split took place on February 26, 2025 with a 30:1 split ratio.

As of March 31, 2025, Aptose Biosciences Inc. has an Altman Z-Score of -111.93, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.